ALKBH5 has been employed in anti‐PD‐1 immunotherapy to regulate lactic acid levels in the tumor microenvironment (TME) and manage the accumulation of Tregs and myeloid‐derived suppressor cells (MDSCs). This evidence concerns the gene ALKBH5 and neoplasm.